Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The Food and Drug Administration recently approved the use of palivizumab (palē-vizhū-mäb), an intramuscularly administered monoclonal antibody preparation. Recommendations for its use are based on a large, randomized study demonstrating a 55% reduction in the risk of hospitalization attributable to respiratory syncytial virus (RSV) infections in high-risk pediatric patients. Infants and children with chronic lung disease (CLD), formerly designated bronchopulmonary dysplasia, as well as prematurely born infants without CLD experienced a reduced number of hospitalizations while receiving palivizumab compared with a placebo. Both palivizumab and respiratory syncytial virus immune globulin intravenous (RSV-IGIV) are available for protecting high-risk children against serious complications from RSV infections. Palivizumab is preferred for most high-risk children because of ease of administration (intramuscular), lack of interference with measles–mumps–rubella vaccine and varicella vaccine, and lack of complications associated with intravenous administration of human immune globulin products. RSV-IGIV, however, provides additional protection against other respiratory viral illnesses and may be preferred for selected high-risk children including those receiving replacement intravenous immune globulin because of underlying immune deficiency or human immuno-deficiency virus infection. For premature infants about to be discharged from hospitals during the RSV season, physicians could consider administering RSV-IGIV for the first month of prophylaxis. Most of the guidelines from the American Academy of Pediatrics for the selection of infants and children to receive RSV-prophylaxis remain unchanged. Palivizumab has been shown to provide benefit for infants who were 32 to 35 weeks of gestation at birth. RSV-IGIV is contraindicated and palivizumab is not recommended for children with cyanotic congenital heart disease. The number of patients with adverse events judged to be related to palivizumab was similar to that of the placebo group (11% vs 10%, respectively); discontinuation of injections for adverse events related to palivizumab was rare.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The IMpact-RSV Study Group (1998) · Pediatrics · doi:10.1542/peds.102.3.531 · Cited by 1,961
Report of the Committee on Infectious Diseases
Nider, H. (1989) · Archives of Dermatology · doi:10.1001/archderm.1989.01670190156031 · Cited by 1,911
Chanock, R. M., Kim, H. W., Brandt, C., & Parrott, R. H. (1976) · Viral Infections of Humans · doi:10.1007/978-1-4613-3988-5_17 · Cited by 1,085
Groothuis, J. R., Simoes, E., Levin, M. J., Hall, C. B., Long, C. E., Rodriguez, W. J., Arrobio, J., Meissner, H. C., Fulton, D. R., Welliver, R. C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311183292102 · Cited by 744
Respiratory Syncytial Viral Infection in Children with Compromised Immune Function
Hall, C. B., Powell, K. R., MacDonald, N. E., Gala, C. L., Menegus, M. E., Suffin, S. C., & Cohen, H. J. (1986) · New England Journal of Medicine · doi:10.1056/nejm198607103150201 · Cited by 655
Johnson, S., Oliver, C., Prince, G. A., Hemming, V. G., Pfarr, D. S., Wang, S., Dormitzer, M., O'Grady, J., Koenig, S., Tamura, J. K., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/514115 · Cited by 641
Respiratory Syncytial Viral Infection in Infants with Congenital Heart Disease
MacDonald, N. E., Hall, C. B., Suffin, S. C., Alexson, C., Harris, P. J., & Manning, J. A. (1982) · New England Journal of Medicine · doi:10.1056/nejm198208123070702 · Cited by 608
The PREVENT Study Group (1997) · Pediatrics · doi:10.1542/peds.99.1.93 · Cited by 450
Respiratory Syncytial Virus Infection in Children With Bronchopulmonary Dysplasia
Groothuis, J. R., Gutierrez, K. M., & Lauer, B. A. (1988) · PEDIATRICS · doi:10.1542/peds.82.2.199 · Cited by 377
Dankner, W. M. (1997) · Clinical Pediatrics · doi:10.1177/000992289703601013 · Cited by 313
SIVA SUBRAMANIAN, K. N., WEISMAN, L. E., RHODES, T., ARIAGNO, R., SÁNCHEZ, P. J., STEICHEN, J., GIVNER, L. B., JENNINGS, T. L., TOP, F. H., CARLIN, D., et al. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199802000-00006 · Cited by 226
Madge, P., Paton, J. Y., McColl, J. H., & Mackie, P. L. K. (1992) · The Lancet · doi:10.1016/0140-6736(92)93088-5 · Cited by 201
Simoes, E. A. F., Sondheimer, H. M., Top, F. H., Meissner, H. C., Welliver, R. C., Kramer, A. A., & Groothuis, J. R. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70056-3 · Cited by 176
Halsey, N. A., Chesney, P. J., Gerber, M. A., Gromisch, D. S., Kohl, S., Marcy, S. M., Marks, M. I., Murray, D. L., Overall, J. C., Pickering, L. K., et al. (1996) · PubMed · Cited by 172
Respiratory Syncytial Virus Immune Globulin Intravenous: Indications for Use
(1997) · PEDIATRICS · doi:10.1542/peds.99.4.645 · Cited by 107
Robbins, J. M., Tilford, J. M., Jacobs, R. F., Wheeler, J. G., Gillaspy, S. R., & Schutze, G. E. (1998) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.152.4.358 · Cited by 46
Nachman, S., Navaie‐Waliser, M., & Qureshi, M. Z. (1997) · PEDIATRICS · doi:10.1542/peds.100.6.e8 · Cited by 44
O’Shea, T. M., Sevick, M. A., & Givner, L. B. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199807000-00003 · Cited by 43
Cited by
Respiratory Syncytial Virus and Parainfluenza Virus
Hall, C. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442507 · Cited by 1,233
COMMITTEE ON INFECTIOUS DISEASES AND BRONCHIOLITIS GUIDELINES COMMITTEE, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., et al. (2014) · Pediatrics · doi:10.1542/peds.2014-1665 · Cited by 771
Viral Bronchiolitis in Children
Meissner, H. C. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1413456 · Cited by 714
Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid
Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000) · The Journal of Pediatrics · doi:10.1067/mpd.2000.110531 · Cited by 688
Metadata
- Authors
- Committee on Infectious Diseases and Committee on Fetus and Newborn
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 1998-11-01
- Volume
- 102
- Issue
- 5
- Pages
- 1211-1216
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2137511411
- Cited by
- 408
- References
- 18
- FWCI
- 24.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.